News | January 31, 2022
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
It would be the first protein-based alternative available in Israel
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Biocon has reported consolidated financial results for the period ended December 31, 2021
First launches expected in H1 2022
Subscribe To Our Newsletter & Stay Updated
